🍽️ d-cycloserine (antibiotic)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Tuberculosis (TB): D-Cycloserine is used as a second-line treatment for tuberculosis, especially when first-line drugs such as isoniazid and rifampicin are ineffective or when the TB bacteria are resistant to them. It works by inhibiting the synthesis of mycobacterial cell walls, thereby killing the bacteria or preventing their growth.

  2. Multi-Drug Resistant Tuberculosis (MDR-TB): D-Cycloserine is particularly useful in the treatment of multi-drug resistant tuberculosis (MDR-TB), a form of TB that is resistant to at least isoniazid and rifampicin, the two most potent anti-TB drugs. D-Cycloserine is often used in combination with other second-line drugs to effectively treat MDR-TB infections.

  3. Extensively Drug Resistant Tuberculosis (XDR-TB): D-Cycloserine may also be used in the treatment of extensively drug-resistant tuberculosis (XDR-TB), which is resistant to multiple first-line and second-line anti-TB drugs. In combination with other antibiotics, d-cycloserine can help combat XDR-TB infections.

  4. Adverse Effects: Common side effects of d-cycloserine include dizziness, drowsiness, headache, nausea, vomiting, and diarrhea. It can also cause neurological side effects such as confusion, depression, anxiety, and hallucinations, particularly at higher doses. Long-term use of d-cycloserine may lead to peripheral neuropathy.

  5. Monitoring: Patients taking d-cycloserine should be closely monitored for adverse effects, especially neurological side effects. Regular assessment of kidney function and liver function may also be necessary. Dosage adjustments or discontinuation of the medication may be required if severe adverse effects occur.

  6. Drug Interactions: D-Cycloserine may interact with other medications, including certain antidepressants, antipsychotics, and anticonvulsants, potentially leading to increased side effects or reduced efficacy of either drug. Healthcare providers should be aware of potential drug interactions and adjust medication doses as needed.

  7. Treatment Duration: The duration of treatment with d-cycloserine for tuberculosis varies depending on the severity of the infection, the presence of drug resistance, and other factors. Treatment regimens are typically prolonged, often lasting for several months to years, and may involve combination therapy with multiple antibiotics.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of d-cycloserine (antibiotic) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces

Bacteria Impacted by d-cycloserine (antibiotic)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Phocaeicola genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Coprococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Clostridium genus Decreases 👪 Source Study Pathogen
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Roseburia intestinalis species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Coprococcus comes species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of d-cycloserine (antibiotic) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.2 0.2
ADHD 0.9 0.3 2
Age-Related Macular Degeneration and Glaucoma 0.4 0.4
Allergic Rhinitis (Hay Fever) 1.2 1.2
Allergies 1.2 0.5 1.4
Allergy to milk products 0.8 0.2 3
Alzheimer's disease 2.4 2.1 0.14
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.3 0.5 1.6
Ankylosing spondylitis 1.3 1.3 0
Anorexia Nervosa 0.7 -0.7
Antiphospholipid syndrome (APS) 1.8 0.2 8
Asthma 0.1 0.6 -5
Atherosclerosis 0.4 1.2 -2
Atrial fibrillation 0.8 1 -0.25
Autism 4 3.6 0.11
Barrett esophagus cancer 0.4 0.2 1
benign prostatic hyperplasia 0.2 0.2
Biofilm 1.9 1.9
Bipolar Disorder 0.6 0.7 -0.17
Brain Trauma 0.6 -0.6
Cancer (General) 0.2 -0.2
Carcinoma 0.8 0.2 3
Celiac Disease 1.7 0.4 3.25
Cerebral Palsy 0.3 0.6 -1
Chronic Fatigue Syndrome 2.3 2.6 -0.13
Chronic Kidney Disease 1.1 0.7 0.57
Chronic Lyme 0.6 -0.6
Chronic Obstructive Pulmonary Disease (COPD) 1.4 0.7 1
Chronic Urticaria (Hives) 1 1.2 -0.2
Coagulation / Micro clot triggering bacteria 0.9 0.6 0.5
Colorectal Cancer 3.9 3.9
Constipation 1.2 0.4 2
Coronary artery disease 0.7 0.3 1.33
COVID-19 2.1 4.4 -1.1
Crohn's Disease 4.6 2.1 1.19
cystic fibrosis 0.7 0.6 0.17
deep vein thrombosis 0.7 0.6 0.17
Depression 2.8 2.2 0.27
Dermatomyositis 0.2 0.2
Eczema 0.9 1.8 -1
Endometriosis 1.4 1.4
Eosinophilic Esophagitis 0.4 0.4
Epilepsy 1.8 0.2 8
Fibromyalgia 0.5 1.6 -2.2
Functional constipation / chronic idiopathic constipation 3.3 2.2 0.5
gallstone disease (gsd) 0.3 0.7 -1.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.9 0.2 8.5
Generalized anxiety disorder 1.7 0.7 1.43
giant cell arteritis 0.1 -0.1
Glioblastoma 0.2 -0.2
Gout 0.3 -0.3
Graves' disease 0.2 0.4 -1
Halitosis 0.6 0.2 2
Hashimoto's thyroiditis 0.6 0.4 0.5
Hidradenitis Suppurativa 0.7 0.7
High Histamine/low DAO 1.1 1.1
hypercholesterolemia (High Cholesterol) 0.1 0.1
hyperglycemia 0.2 0.2 0
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 0.6 2.4 -3
Hypothyroidism 0.3 -0.3
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 1.8 -1.8
Inflammatory Bowel Disease 3.3 3 0.1
Insomnia 0.4 0.6 -0.5
Intelligence 0.6 0.4 0.5
Intracranial aneurysms 0.2 0.2
Irritable Bowel Syndrome 1.8 1.6 0.13
Liver Cirrhosis 2 1.4 0.43
Long COVID 3.6 1.8 1
Low bone mineral density 0.7 -0.7
Lung Cancer 0.2 0.2
Mast Cell Issues / mastitis 0.4 0.3 0.33
ME/CFS with IBS 0.3 0.9 -2
ME/CFS without IBS 1.1 0.2 4.5
Metabolic Syndrome 3.9 3.5 0.11
Mood Disorders 3.5 2.2 0.59
multiple chemical sensitivity [MCS] 0.9 0.9
Multiple Sclerosis 1.5 2.3 -0.53
Multiple system atrophy (MSA) 0 0
neuropathic pain 0.2 -0.2
Neuropathy (all types) 0.2 0.2 0
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1 0.6 0.67
Obesity 2.3 1.7 0.35
obsessive-compulsive disorder 2.8 1.7 0.65
Osteoarthritis 1.4 1.4
Osteoporosis 0.5 0.2 1.5
pancreatic cancer 0.2 0.2
Parkinson's Disease 1.2 3 -1.5
Polycystic ovary syndrome 1.3 0.5 1.6
Postural orthostatic tachycardia syndrome 0.1 0.3 -2
primary biliary cholangitis 0.2 -0.2
Psoriasis 1.5 1.4 0.07
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3.4 2.2 0.55
Rosacea 0.5 -0.5
Schizophrenia 1.2 0.8 0.5
scoliosis 0.3 0.2 0.5
Sjögren syndrome 0.9 0.4 1.25
Sleep Apnea 0.7 0.9 -0.29
Slow gastric motility / Gastroparesis 0.7 0.7
Small Intestinal Bacterial Overgrowth (SIBO) 1 1
Stress / posttraumatic stress disorder 1.5 0.9 0.67
Systemic Lupus Erythematosus 3 0.4 6.5
Tic Disorder 0.8 0.4 1
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 2.5 1.5 0.67
Type 2 Diabetes 4.6 4.2 0.1
Ulcerative colitis 1.2 2.6 -1.17
Unhealthy Ageing 4.3 0.7 5.14

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]